| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Markianos, J Hatzimanolis, L Lykoura. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone. Psychopharmacology. vol 157. issue 1. 2001-10-25. PMID:11512043. |
the pharmacological profile of risperidone is that of an atypical neuroleptic regarding its serotonin 5-ht2a and dopamine d2 receptor blocking properties. |
2001-10-25 |
2023-08-12 |
Not clear |
| O G Heitu. [Risperidone as a tool to control hard aggression]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. vol 121. issue 19. 2001-10-25. PMID:11571877. |
risperidone is an antipsychotic drug with a combined effect as a dopamine antagonist and a 5-ht2a receptor antagonist. |
2001-10-25 |
2023-08-12 |
Not clear |
| M Van Bellinghen, C De Troc. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. Journal of child and adolescent psychopharmacology. vol 11. issue 1. 2001-08-30. PMID:11322745. |
risperidone, an antipsychotic agent with combined serotonin (5-ht2a) and dopamine (d2) receptor-blocking properties, is associated with fewer extrapyramidal side effects in adults than conventional neuroleptics. |
2001-08-30 |
2023-08-12 |
Not clear |
| E Richelson, T Soude. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life sciences. vol 68. issue 1. 2001-01-11. PMID:11132243. |
using radioligand binding assays and post-mortem normal human brain tissue, we obtained equilibrium dissociation constants (k(d)s) for nine new antipsychotic drugs (iloperidone, melperone, olanzapine, org 5222, quetiapine, risperidone, sertindole, ziprasidone, and zotepine), one metabolite of a new drug (9-oh-risperidone), and three older antipsychotics (clozapine, haloperidol, and pimozide) at nine different receptors (alpha1-adrenergic, alpha2-adrenergic, dopamine d2, histamine h1, muscarinic, and serotonin 5-ht1a, 5-ht1d, 5-ht2a, and 5-ht2c receptors). |
2001-01-11 |
2023-08-12 |
human |
| N Bhana, C M Spence. Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs & aging. vol 16. issue 6. 2000-11-30. PMID:10939309. |
risperidone has antagonistic activity primarily at serotonin 5-ht2a and dopamine d2 receptors. |
2000-11-30 |
2023-08-12 |
Not clear |
| I Kusumi, Y Takahashi, K Suzuki, K Kameda, T Koyam. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. Journal of neural transmission (Vienna, Austria : 1996). vol 107. issue 3. 2000-08-02. PMID:10821438. |
the effects of 3-week treatment with a typical antipsychotic drug chlorpromazine and three atypical antipsychotic drugs (risperidone, olanzapine and perospirone) on the binding to dopamine d2 and serotonin 5-ht2a receptors were examined in the rat stratum and frontal cortex, respectively. |
2000-08-02 |
2023-08-12 |
rat |
| I Kusumi, Y Takahashi, K Suzuki, K Kameda, T Koyam. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. Journal of neural transmission (Vienna, Austria : 1996). vol 107. issue 3. 2000-08-02. PMID:10821438. |
on the other hand, 3-week administration of chlorpromazine (5, 10 mg/kg) and olanzapine (1, 2 mg/kg) significantly decreased 5-ht2a receptors, but risperidone (0.25, 0.5 mg/kg) or perospirone (0.1, 1 mg/kg) had no effect. |
2000-08-02 |
2023-08-12 |
rat |
| N A Moor. Behavioural pharmacology of the new generation of antipsychotic agents. The British journal of psychiatry. Supplement. issue 38. 2000-07-31. PMID:10884895. |
risperidone, sertindole and ziprasidone have profiles of activity different from those of older agents, predominantly due to their 5-ht2a affinity. |
2000-07-31 |
2023-08-12 |
Not clear |
| N A Leopol. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Movement disorders : official journal of the Movement Disorder Society. vol 15. issue 2. 2000-06-09. PMID:10752580. |
risperidone, a novel neuroleptic with approximately equal d2 and 5ht2a receptor blocking properties, has been used to treat drug-related hallucinations in patients with parkinson's disease. |
2000-06-09 |
2023-08-12 |
Not clear |
| E C Lauterbach, A Abdelhamid, J B Annandal. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade. Pharmacopsychiatry. vol 33. issue 1. 2000-05-10. PMID:10721882. |
posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5ht2a receptor blockade. |
2000-05-10 |
2023-08-12 |
Not clear |
| I Ninan, S K Kulkarn. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics. Methods and findings in experimental and clinical pharmacology. vol 21. issue 9. 2000-02-28. PMID:10669905. |
the effect of the selective dopamine d2 receptor agonist quinpirole, the selective 5-ht1a receptor agonist 8-oh-dpat and the selective 5-ht2a receptor antagonist ketanserin on catalepsy induced by atypical antipsychotics clozapine, risperidone, olanzapine and sertindole at higher doses was studied in rats. |
2000-02-28 |
2023-08-12 |
mouse |
| S Chaki, T Funakoshi, R Yoshikawa, S Okuyama, T Kumagai, A Nakazato, M Nagamine, K Tomisaw. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology. vol 38. issue 8. 1999-10-12. PMID:10462131. |
in the present study, in vivo receptor occupancy of 5-ht2a, alpha1, dopamine d2 and d3 receptors by nra0045 was assessed, based on in vivo and ex vivo receptor binding, and findings were compared to reference antipsychotic drugs (haloperidol, risperidone, clozapine). |
1999-10-12 |
2023-08-12 |
rat |
| S Chaki, T Funakoshi, R Yoshikawa, S Okuyama, T Kumagai, A Nakazato, M Nagamine, K Tomisaw. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology. vol 38. issue 8. 1999-10-12. PMID:10462131. |
by contrast, atypical antipsychotics such as risperidone and clozapine dose-dependently occupied the 5-ht2a receptor in the frontal cortex, with moderate to negligible occupancy of the d2 receptor in the striatum and the nucleus accumbens. |
1999-10-12 |
2023-08-12 |
rat |
| H Y Meltze. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 21. issue 2 Suppl. 1999-09-17. PMID:10432496. |
recent interest in the role of serotonin (5-ht) in antipsychotic drug action is based mainly upon the fact that antipsychotic drugs such as clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone are potent 5-ht2a receptor antagonists and relatively weaker dopamine d2 antagonists. |
1999-09-17 |
2023-08-12 |
Not clear |
| B Gallhofer, S Lis, A Meyer-Lindenberg, S Kriege. Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta psychiatrica Scandinavica. Supplementum. vol 395. 1999-06-28. PMID:10225341. |
the concept of maze-solving behaviour as a continuous cognitive task evoking a conflict between prefrontal cortex and basal ganglia activity is explained and introduced to distinguish between the effects of d2 blocking agents and substances with a predominant 5ht2a receptor affinity, such as clozapine and risperidone. |
1999-06-28 |
2023-08-12 |
Not clear |
| S Nyberg, B Eriksson, G Oxenstierna, C Halldin, L Fard. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. The American journal of psychiatry. vol 156. issue 6. 1999-06-16. PMID:10360125. |
suggested minimal effective dose of risperidone based on pet-measured d2 and 5-ht2a receptor occupancy in schizophrenic patients. |
1999-06-16 |
2023-08-12 |
Not clear |
| S Nyberg, B Eriksson, G Oxenstierna, C Halldin, L Fard. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. The American journal of psychiatry. vol 156. issue 6. 1999-06-16. PMID:10360125. |
the aim of this positron emission tomography (pet) study was to suggest a minimal effective dose of risperidone based on measurements of dopamine d2 and serotonin 5-ht2a receptor occupancy. |
1999-06-16 |
2023-08-12 |
Not clear |
| H Y Meltzer, K Jayathilak. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine? The Journal of clinical psychiatry. vol 60 Suppl 10. 1999-05-27. PMID:10340687. |
however, as is the case for risperidone, the occupancy of 5-ht2a and d2 receptors can range from partial to full, depending upon the dose. |
1999-05-27 |
2023-08-12 |
Not clear |
| N Takahashi, T Terao, T Oga, M Okad. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. vol 39. issue 2. 1999-05-19. PMID:10072664. |
the ratio between 5ht2a and d2 receptor occupancy) and mosapramine (low 5ht2a/d2 ratio) in a randomized, single-blind, crossover, add-on study consisting of 8 weeks of treatment each with risperidone and mosapramine. |
1999-05-19 |
2023-08-12 |
Not clear |
| M J Travis, G F Busatto, L S Pilowsky, R Mulligan, P D Acton, S Gacinovic, J Mertens, D Terrière, D C Costa, P J Ell, R W Kerwi. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. The British journal of psychiatry : the journal of mental science. vol 173. 1999-02-09. PMID:9926100. |
5-ht2a receptor blockade in patients with schizophrenia treated with risperidone or clozapine. |
1999-02-09 |
2023-08-12 |
Not clear |